A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
A phase 3 trial of Rilvegostomig, Durvalumab and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, now recruiting.
Overview
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) is a phase 3 interventional study registered as NCT07221253 by AstraZeneca, with 1100 participants planned, started 2025-12-04 and due to reach its primary completion in 2029-07-31. Interventions recorded: Rilvegostomig, Durvalumab and Gemcitabine/Cisplatin.
Similar pages
not linked directly; found by shared links- TrialRilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Shares Gemcitabine + cisplatin, Rilvegostomig, Biliary tract cancer (cholangiocarcinoma), AstraZeneca and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Rilvegostomig, Durvalumab, Biliary tract cancer (cholangiocarcinoma), AstraZeneca and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma), AstraZeneca and the tag pipeline.
- TrialAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Gemcitabine + cisplatin, Durvalumab, AstraZeneca and the tag pipeline.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
- TrialPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Shares Gemcitabine + cisplatin, Durvalumab, AstraZeneca and the tag pipeline.